122 related articles for article (PubMed ID: 6392304)
1. Excretion of modified nucleosides during development of malignant lymphomas in mice after whole body irradiation.
Thomale J; Luz A; Nass G
J Cancer Res Clin Oncol; 1984; 108(3):302-7. PubMed ID: 6392304
[TBL] [Abstract][Full Text] [Related]
2. Increased urinary levels of RNA catabolites in mice as early indicators for malignant growth.
Thomale J; Luz A; Nass G
Cancer Detect Prev; 1983; 6(1-2):73-6. PubMed ID: 6192923
[TBL] [Abstract][Full Text] [Related]
3. Modified nucleosides in body fluids of tumor-bearing patients.
Salvatore F; Colonna A; Costanzo F; Russo T; Esposito F; Cimino F
Recent Results Cancer Res; 1983; 84():360-77. PubMed ID: 6844698
[TBL] [Abstract][Full Text] [Related]
4. Increasing urinary levels of modified nucleosides and bases during tumor development in mice.
Thomale J; Nass G
Recent Results Cancer Res; 1983; 84():378-87. PubMed ID: 6844699
[TBL] [Abstract][Full Text] [Related]
5. Urinary excretion of modified nucleosides as biological marker of RNA turnover in patients with cancer and AIDS.
Nakano K; Nakao T; Schram KH; Hammargren WM; McClure TD; Katz M; Petersen E
Clin Chim Acta; 1993 Sep; 218(2):169-83. PubMed ID: 7508341
[TBL] [Abstract][Full Text] [Related]
6. Urinary nucleosides in leukemia: laboratory and clinical applications.
Trewyn RW; Grever MR
Crit Rev Clin Lab Sci; 1986; 24(1):71-93. PubMed ID: 3539520
[TBL] [Abstract][Full Text] [Related]
7. Differential excretion of modified nucleosides in adult acute leukemia.
Heldman DA; Grever MR; Trewyn RW
Blood; 1983 Feb; 61(2):291-6. PubMed ID: 6571786
[TBL] [Abstract][Full Text] [Related]
8. [Investigation of urinary nucleosides excretion of intestinal cancer patients by reversed-phase high performance liquid chromatography].
Zheng YF; Chen YJ; Pang T; Shi XZ; Kong HW; Lü S; Yang Q; Xu GW
Se Pu; 2002 Nov; 20(6):498-501. PubMed ID: 12682995
[TBL] [Abstract][Full Text] [Related]
9. Excretion pattern investigation of urinary normal and modified nucleosides of breast cancer patients by RP-HPLC and factor analysis method.
Xu G; Schmid HR; Lu X; Liebich HM; Lu P
Biomed Chromatogr; 2000 Nov; 14(7):459-63. PubMed ID: 11113924
[TBL] [Abstract][Full Text] [Related]
10. Radiation leukemogenesis: quantitative relationship between pre-leukemic cells in the thymus and lymphoma induction.
Kotler M; Ruchlemer R; Avni O; Yefenof E
Int J Cancer; 1994 Mar; 56(5):761-5. PubMed ID: 8314355
[TBL] [Abstract][Full Text] [Related]
11. Modified nucleosides as biomarkers for early cancer diagnose in exposed populations.
Seidel A; Seidel P; Manuwald O; Herbarth O
Environ Toxicol; 2015 Jul; 30(8):956-67. PubMed ID: 24615900
[TBL] [Abstract][Full Text] [Related]
12. Pseudouridine: a modified nucleoside as biological marker in malignant lymphomas.
Rasmuson T; Björk GR
Cancer Detect Prev; 1983; 6(1-2):293-6. PubMed ID: 6883387
[TBL] [Abstract][Full Text] [Related]
13. Analysis of modified nucleosides in the urine of patients with malignant cancer by liquid chromatography/electrospray ionization mass spectrometry.
Li HY; Wang SM; Liu HM; Li J; Han D; Bu SS; Zhang MZ
Rapid Commun Mass Spectrom; 2008 Oct; 22(20):3161-71. PubMed ID: 18798199
[TBL] [Abstract][Full Text] [Related]
14. X-ray-induced lymphomagenesis in E mu-pim-1 transgenic mice: an investigation of the co-operating molecular events.
van der Houven van Oordt CW; Schouten TG; van Krieken JH; van Dierendonck JH; van der Eb AJ; Breuer ML
Carcinogenesis; 1998 May; 19(5):847-53. PubMed ID: 9635873
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase, and modified nucleosides as biological markers in malignant lymphomas.
Rasmuson T; Björk GR; Damber L; Holm SE; Jacobsson L; Jeppsson A; Littbrand B; Stigbrand T; Westman G
Recent Results Cancer Res; 1983; 84():331-43. PubMed ID: 6342073
[TBL] [Abstract][Full Text] [Related]
16. Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control.
Seidel A; Brunner S; Seidel P; Fritz GI; Herbarth O
Br J Cancer; 2006 Jun; 94(11):1726-33. PubMed ID: 16685264
[TBL] [Abstract][Full Text] [Related]
17. Reversed-phase high-performance liquid chromatographic investigation of mucosal nucleosides and bases and urinary modified nucleosides of gastrointestinal cancer patients.
Nakano K; Shindo K; Yasaka T; Yamamoto H
J Chromatogr; 1985 Sep; 343(1):21-33. PubMed ID: 4066857
[TBL] [Abstract][Full Text] [Related]
18. Capillary electrophoresis of urinary normal and modified nucleosides of cancer patients.
Xu G; Liebich HM; Lehmann R; Müller-Hagedorn S
Methods Mol Biol; 2001; 162():459-74. PubMed ID: 11217356
[No Abstract] [Full Text] [Related]
19. Reversed-phase high-performance liquid chromatographic investigation of urinary normal and modified nucleosides of cancer patients.
Xu G; Di Stefano C; Liebich HM; Zhang Y; Lu P
J Chromatogr B Biomed Sci Appl; 1999 Sep; 732(2):307-13. PubMed ID: 10517352
[TBL] [Abstract][Full Text] [Related]
20. Relationship of urinary excretion of modified nucleosides to disease status in childhood acute lymphoblastic leukemia.
Heldman DA; Grever MR; Miser JS; Trewyn RW
J Natl Cancer Inst; 1983 Aug; 71(2):269-73. PubMed ID: 6576186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
